Court Report - June 24, 2012

[author: Sherri Oslick]

Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Bristol-Myers Squibb Company v. Sandoz Inc.
1:12-cv-00787; filed June 21, 2012 in the District Court of Delaware

Infringement of U.S. Patent No. 5,206,244 ("Hydroxymethyl (Methylenecyclopentyl) Purines and Pyrimidines," issued April 27, 1993) following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of BMS's Baraclude® (entecavir, used to treat chronic hepatitis B virus infectrion).  View the complaint here.

Illumina, Inc. et al. v. Complete Genomics, Inc. et al.
3:12-cv-01465; filed June 15, 2012 in the Southern District of California

• Plaintiffs:  Illumina, Inc.; Illumina Cambridge Ltd.
• Defendants:  Complete Genomics, Inc.; DOES 1-50, inclusive

Infringement of U.S. Patent No. 8,192,930 ("Method for Sequencing a Polynucleotide Template," issued June 5, 2012) based on Complete Genomic's manufacture, use, sale, and/or offer for sale of products, services, methods and/or systems, under the moniker "COMPLETE GENOMICS Analysis Platform."  View the complaint here.

Janssen Products, L.P. et al. v. Teva Pharmaceuticals USA, Inc. et al.
2:12-cv-03569; filed June 13, 2012 in the District Court of New Jersey

• Plaintiffs:  Janssen Products, L.P.; Janssen R&D Ireland; G.D. Searle, LLC
• Defendants:  Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.

Infringement of U.S. Patent No. RE42,889 ("α- and β-Amino Acid Hydroxyethylamino Sulfonamides Useful as Retroviral Protease Inhibitors," issued November 1, 2011) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Janssen's Prezista® (darunavir, used to treat human immunodeficiency virus (HIV-1) infection).  View the complaint here.